These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 25323938

  • 21. Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.
    Okamoto K, Okamoto I, Hatashita E, Kuwata K, Yamaguchi H, Kita A, Yamanaka K, Ono M, Nakagawa K.
    Mol Cancer Ther; 2012 Jan; 11(1):204-13. PubMed ID: 22075159
    [Abstract] [Full Text] [Related]

  • 22. Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer.
    Lara MS, Holland WS, Chinn D, Burich RA, Lara PN, Gandara DR, Kelly K, Mack PC.
    Clin Lung Cancer; 2017 May; 18(3):281-285. PubMed ID: 28038979
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines.
    Puglisi M, Thavasu P, Stewart A, de Bono JS, O'Brien ME, Popat S, Bhosle J, Banerji U.
    Lung Cancer; 2014 Aug; 85(2):141-6. PubMed ID: 24957682
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
    Chang X, Izumchenko E, Solis LM, Kim MS, Chatterjee A, Ling S, Monitto CL, Harari PM, Hidalgo M, Goodman SN, Wistuba II, Bedi A, Sidransky D.
    PLoS One; 2013 Aug; 8(7):e68966. PubMed ID: 23935914
    [Abstract] [Full Text] [Related]

  • 30. Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.
    Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Segura-Carretero A, Joven J, Martin-Castillo B, Barrajón-Catalán E, Micol V, Bosch-Barrera J, Menendez JA.
    Cell Cycle; 2013 Nov 01; 12(21):3390-404. PubMed ID: 24047698
    [Abstract] [Full Text] [Related]

  • 31. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J.
    BMC Med; 2012 Mar 21; 10():28. PubMed ID: 22436374
    [Abstract] [Full Text] [Related]

  • 32. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.
    Tang Z, Du R, Jiang S, Wu C, Barkauskas DS, Richey J, Molter J, Lam M, Flask C, Gerson S, Dowlati A, Liu L, Lee Z, Halmos B, Wang Y, Kern JA, Ma PC.
    Br J Cancer; 2008 Sep 16; 99(6):911-22. PubMed ID: 19238632
    [Abstract] [Full Text] [Related]

  • 33. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.
    Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, Maehara Y, Yatabe Y, Mitsudomi T.
    Clin Cancer Res; 2010 Nov 15; 16(22):5489-98. PubMed ID: 21062933
    [Abstract] [Full Text] [Related]

  • 34. Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity.
    Buck E, Eyzaguirre A, Haley JD, Gibson NW, Cagnoni P, Iwata KK.
    Mol Cancer Ther; 2006 Aug 15; 5(8):2051-9. PubMed ID: 16928826
    [Abstract] [Full Text] [Related]

  • 35. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
    Tong X, Jiang P, Li Y, Guo L, Zhang HM, Zhang BK, Yan M.
    Chem Pharm Bull (Tokyo); 2019 Aug 01; 67(8):864-871. PubMed ID: 31142691
    [Abstract] [Full Text] [Related]

  • 36. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
    Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, Pomper MG, Kim J, Laterra J.
    Mol Cancer Ther; 2009 Jul 01; 8(7):1751-60. PubMed ID: 19584231
    [Abstract] [Full Text] [Related]

  • 37. Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells.
    Serizawa M, Murakami H, Watanabe M, Takahashi T, Yamamoto N, Koh Y.
    Cancer Sci; 2014 Jun 01; 105(6):683-9. PubMed ID: 24698130
    [Abstract] [Full Text] [Related]

  • 38. Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors.
    Ghosh G, Lian X, Kron SJ, Palecek SP.
    BMC Cancer; 2012 Mar 20; 12():95. PubMed ID: 22433462
    [Abstract] [Full Text] [Related]

  • 39. Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/FBXW7 pathway.
    Zhang H, Chen F, He Y, Yi L, Ge C, Shi X, Tang C, Wang D, Wu Y, Nian W.
    Biosci Rep; 2017 Jun 30; 37(3):. PubMed ID: 28507201
    [Abstract] [Full Text] [Related]

  • 40. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
    Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, Goetz EM, Letai A, Garraway LA, Lazzara MJ, Rosen N, Gray NS, Wong KK, Jänne PA.
    Cancer Discov; 2012 Oct 30; 2(10):934-47. PubMed ID: 22961667
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.